Search results
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in...
Morningstar· 4 days ago(Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced sustained positive results from PROPEL ...
Massive federal grant ensures University of Michigan can continue retirement study through 2029
ClickOnDetroit· 3 days agoThis is the largest research grant in University of Michigan history, according to a press release. ...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 3 days agoThe prize has been awarded annually since 2006 to honor an outstanding scientist whose body of work...
Docetaxel Tied to Less Taxane Neuropathy in Black Breast Cancer Patients
MedPage Today· 3 days agoThe primary purpose of the study was to validate whether certain genetic variants confer a high risk...
Neurolixis expands rare autism disorders research program
Digital Journal· 4 days agoFXS is a rare genetic autism spectrum disorder which affects about 1 in 5000 individuals and is a leading cause of inherited intellectual disability. There are no approved ...
She's the world's most expensive cow, and part of Brazil's plan to put beef on everyone's plate
KEYT 3 Santa Barbara· 4 days agoBrazil has hundreds of millions of cows, but one in particular is extraordinary. Worth $4 million,...
23andMe reports positive phase 2 data for cancer drug By Investing.com
Investing.com· 5 days agoThe data was presented at the American Society of Clinical Oncology Annual Meeting, which took place...
Can tattoos increase the risk of cancer?
Hardwood Paroxysm· 3 days agoTattooing has accompanied humanity since ancient times in various cultures, but its practice… Get a tattoo Part of the body It has had different...
Lilly announces departure of Anat Ashkenazi, chief financial officer - Eli Lilly and Co (NYSE:LLY)
Benzinga· 3 days agoEli Lilly and Company LLY announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry ...
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...
The Woonsocket Call· 7 days agoEli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced ...